Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept dose-to-target tapering trial in RA, AS, and PsA
NL-OMON38584Recruiting
- Sponsor
- Jan van Breemen Institute
- Start
- Jul 2013
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of etanercept in rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) (3 arms), sponsored by Jan van Breemen Institute. Primary endpoint: Maintenance of minimal disease activity after etanercept dose interval prolongation. Started Jul 2013; status: recruiting.
02
Drugs
etanercept
03
Conditions
rheumatoid arthritis (RA)ankylosing spondylitis (AS)psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NL-OMON38584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38584.